1 | Initial staging after histologic diagnosis of NETs | Appropriate | 9 |
2 | Localization of primary tumor in patients with known metastatic disease but unknown primary | Appropriate | 9 |
3 | Selection of patients for SSTR-targeted PRRT | Appropriate | 9 |
4 | Staging NETs before planned surgery | Appropriate | 8 |
5 | Evaluation of mass suggestive of NET not amenable to endoscopic or percutaneous biopsy (e.g., ileal lesion, hypervascular pancreatic mass, mesenteric mass) | Appropriate | 8 |
6 | Monitoring of NETs seen predominantly on SSTR PET | Appropriate | 8 |
7 | Evaluation of patients with biochemical evidence and symptoms of NET without evidence on CI and without prior histologic diagnosis of NET | Appropriate | 7 |
8 | Restaging at time of clinical or laboratory progression without progression on CI | Appropriate | 7 |
9 | New indeterminate lesion on CI, with unclear progression | Appropriate | 7 |
10 | Restaging of patients with NETs at initial follow-up after resection with curative intent | May be appropriate | 6 |
11 | Selection of patients with nonfunctional NETs for SSA treatment | May be appropriate | 6 |
12 | Monitoring in patients with NETs seen on both CI and SSTR PET with active disease and no clinical evidence of progression | May be appropriate | 5 |